Equillium, Inc.
- EQ
- NASDAQ
- Biotechnology
- Immuno-Inflammatory Biotech
- Clinical-Stage Therapeutics
$1.24
Today +4.20%Quote Oct 19, 2026, 08:00 PM UTC
−37.04%over the last month
Max drawdown −38.3%From 1-month high −38.3%3 months −51.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Equillium
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
14
Founded
2017
Market value
$78.6M
Quote Oct 19
Floor
$1.22
1.3% below price
Resistance
$1.32
6.2% above price
Price vs analyst targets
12 analysts
Lowest target
$5.00Highest target
$7.00
$5.00Highest target
$7.00
- Price $1.24
- Average target $6.25
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 404% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about EQPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free